Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Rezafungin (Rezzayo) vs Teduglutide (Gattex)
An educational, source-based comparison of Rezafungin (Rezzayo) and Teduglutide (Gattex) — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly echinocandin for candidemia and invasive candidiasis.
Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.
- Candidemia
- Invasive candidiasis
- • FDA-approved (2023).
- • Infusion reactions and photosensitivity reported.
GLP-2 analog for short bowel syndrome dependent on parenteral support.
Recombinant analog of glucagon-like peptide-2 with alanine→glycine substitution at position 2, resisting DPP-IV degradation; promotes intestinal mucosal growth, villus height, and absorptive capacity.
- Short bowel syndrome with intestinal failure
- Reduction of parenteral nutrition dependence
- • FDA-approved.
- • Colorectal polyp surveillance required.
- • Risk of intestinal obstruction and biliary/pancreatic disease.
Rezafungin (Rezzayo) vs Teduglutide (Gattex) — Key differences
- Class: Rezafungin (Rezzayo) is classified as Echinocandin · Antifungal, while Teduglutide (Gattex) is GLP-2 Analog · Gastrointestinal.
- Primary research focus: Rezafungin (Rezzayo) — candidemia; Teduglutide (Gattex) — short bowel syndrome with intestinal failure.
- Tag: FDA-Approved · Antifungal vs FDA-Approved · GI.